• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CT1
Click for more information
0.00% 0.2¢

CONSTELLATION TECHNOLOGIES LIMITED - Announcements

Market Cap $1.474M  ! watchlist Created with Sketch. Add to my watchlist

Constellation Technologies Limited is an Australia-based Internet of things (IoT) and... Constellation Technologies Limited is an Australia-based Internet of things (IoT) and digital solutions company. The Company is focused on offering solutions to market, which leverage cloud, IoT, edge-computing sensors, big data, analytics, machine learning (ML), artificial intelligence (AI) and other advanced technologies. The Company through Callisto offers a range of solutions designed to address various industry needs. These solutions include Food Safety & Compliance, Drugs & Medicine Monitoring, Cold Chain Logistics, and Asset Management. Its Gen3 IoT product line offers IoT devices that can capture critical data points across a range of applications, providing its customers with reliable and flexible solutions that support multiple communication networks and sensor customization. Its MeridianCT is a cloud-based software platform and mobile application, which enables users to have an end-to-end IoT data solution to connect, monitor and visualize their data. More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
CT1 Change in substantial holding17/07/13
CT1 Investor Presentation11/07/13
CT1 Change of Director's Interest Notice - A Lee01/07/13
CT1 Change of Director's Interest Notice - N Weston01/07/13
CT1 Change of Director's Interest Notice - C Chapman01/07/13
CT1 Top 20 securityholders01/07/13
CT1 Appendix 3B01/07/13
CT1 Results of Meeting - EGM27/06/13
CT1 EGM Presentation27/06/13
CT1 Cleansing Notice06/06/13
CT1 Appendix 3B06/06/13
CT1 Proxy Form 27 June2013 EGM30/05/13
CT1 Notice of Extraordinary General Meeting/Proxy Form29/05/13
CT1 Change in substantial holding22/05/13
CT1 Becoming a substantial holder22/05/13
CT1 Becoming a substantial holder22/05/13
CT1 Issued Capital Update and Top 20 Shareholders22/05/13
CT1 Initial Director's Interest Notice21/05/13
CT1 Appendix 3B21/05/13
CT1 Appointment of Non Executive Director21/05/13
CT1 Agenix raises $1 MillionPRICE SENSITIVE17/05/13
CT1 Appendix 3B08/05/13
CT1 Appendix 4C - quarterlyPRICE SENSITIVE29/04/13
CT1 Bio 2013 presentation by Nick Weston CEO22/04/13
CT1 On Track to file New Drug Clinical Trial ApplicationPRICE SENSITIVE27/03/13
CT1 Appendix 3B18/03/13
CT1 Ceasing to be a substantial holder13/03/13
CT1 Appendix 3B and Entitlement Offer Update01/03/13
CT1 Cleansing Notice01/03/13
CT1 Half Yearly Report and Accounts28/02/13
CT1 Top 20 Shareholders and Option Spread25/02/13
CT1 Change of Director's Interest Notice - N Weston22/02/13
CT1 Change of Director's Interest Notice - A Lee22/02/13
CT1 Change of Director's Interest Notice - C McNamara22/02/13
CT1 Appendix 3B21/02/13
CT1 Rights Issue Acceptances and Shortfall21/02/13
CT1 Research Coverage Updated18/02/13
CT1 Rights Issue Update12/02/13
CT1 Investor Presentation12/02/13
CT1 Cleansing Notice04/02/13
CT1 Cleansing Notice04/02/13
CT1 Appendix 3B04/02/13
CT1 Agenix secures $3 Million Continuous Investment AgreementPRICE SENSITIVE31/01/13
CT1 Appendix 4D Preliminary Half Year ReportPRICE SENSITIVE22/01/13
CT1 Appendix 4C - quarterlyPRICE SENSITIVE22/01/13
CT1 Entitlement Offer Timetable and Shareholder Letter22/01/13
CT1 Appendix 3B21/01/13
CT1 Non-Renounceable Entitlement Offer ProspectusPRICE SENSITIVE21/01/13
CT1 Change of Director's Interest Notice07/01/13
CT1 Cleansing Notice07/01/13
CT1 Appendix 3B07/01/13
CT1 Working Capital update and removal of trading haltPRICE SENSITIVE27/12/12
CT1 Change in substantial holding24/12/12
CT1 Request for Trading Halt21/12/12
CT1 Trading HaltPRICE SENSITIVE21/12/12
CT1 Results of Extraordinary General Meeting20/12/12
CT1 Extraordinary General Meeting Presentation20/12/12
CT1 Becoming a substantial holder17/12/12
CT1 Change in substantial holding13/12/12
CT1 Change of Director's Interest Notice13/12/12
CT1 Change of Director's Interest Notice13/12/12
CT1 Change of Director's Interest Notice13/12/12
CT1 Agenix Update and Milestones for 201311/12/12
CT1 Cleansing Notice04/12/12
CT1 Cleansing Notice04/12/12
CT1 Appendix 3B04/12/12
CT1 Notice of Extraordinary General Meeting/Proxy Form22/11/12
CT1 Completion of Share Consolidation16/11/12
CT1 Cleansing Notice - Tyrian02/11/12
CT1 Cleansing Notice - Fortrend02/11/12
CT1 Appendix 3B02/11/12
CT1 Share Consolidation29/10/12
CT1 Results of Annual General Meeting25/10/12
CT1 +Tyrian Licenses Diagnostic Technology To Agenix25/10/12
CT1 Annual General Meeting Presentation25/10/12
CT1 Chairman's Address to ShareholdersPRICE SENSITIVE25/10/12
CT1 +Agenix acquires diagnostic device technology from Tyrian LtdPRICE SENSITIVE25/10/12
CT1 Microcap Investor Presentation17/10/12
CT1 Appendix 4C - quarterlyPRICE SENSITIVE11/10/12
CT1 Notice of Annual General Meeting/Proxy Form21/09/12
CT1 Annual Report to shareholders06/09/12
CT1 Cleansing Notice06/09/12
CT1 Appendix 3B06/09/12
CT1 Agenix Presentation at International Forum05/09/12
CT1 Agenix featured at International ForumPRICE SENSITIVE05/09/12
CT1 Preliminary Final ReportPRICE SENSITIVE24/08/12
CT1 Change in Substantial Shareholder Notice02/08/12
CT1 Cleansing Notice02/08/12
CT1 Appendix 3B02/08/12
CT1 Quarterly Update and Appendix 4C30/07/12
CT1 Appendix 4C - quarterlyPRICE SENSITIVE30/07/12
CT1 Cleansing Notice02/07/12
CT1 Appendix 3B02/07/12
CT1 Lapse of Listed Options02/07/12
CT1 Potential of Thromboview Diagnostic showcase to US Investors15/06/12
CT1 Change in substantial holding06/06/12
CT1 Agenix Hires Former Pfizer Worldwide Business Dev Director04/06/12
CT1 Appendix 3B04/06/12
CT1 Cleansing Notice04/06/12
CT1 Option Expiry Notice31/05/12
CT1 Change in substantial holding
17/07/13
CT1 Investor Presentation
11/07/13
CT1 Change of Director's Interest Notice - A Lee
01/07/13
CT1 Change of Director's Interest Notice - N Weston
01/07/13
CT1 Change of Director's Interest Notice - C Chapman
01/07/13
CT1 Top 20 securityholders
01/07/13
CT1 Appendix 3B
01/07/13
CT1 Results of Meeting - EGM
27/06/13
CT1 EGM Presentation
27/06/13
CT1 Cleansing Notice
06/06/13
CT1 Appendix 3B
06/06/13
CT1 Proxy Form 27 June2013 EGM
30/05/13
CT1 Notice of Extraordinary General Meeting/Proxy Form
29/05/13
CT1 Change in substantial holding
22/05/13
CT1 Becoming a substantial holder
22/05/13
CT1 Becoming a substantial holder
22/05/13
CT1 Issued Capital Update and Top 20 Shareholders
22/05/13
CT1 Initial Director's Interest Notice
21/05/13
CT1 Appendix 3B
21/05/13
CT1 Appointment of Non Executive Director
21/05/13
CT1 Agenix raises $1 Million
17/05/13PRICE SENSITIVE
CT1 Appendix 3B
08/05/13
CT1 Appendix 4C - quarterly
29/04/13PRICE SENSITIVE
CT1 Bio 2013 presentation by Nick Weston CEO
22/04/13
CT1 On Track to file New Drug Clinical Trial Application
27/03/13PRICE SENSITIVE
CT1 Appendix 3B
18/03/13
CT1 Ceasing to be a substantial holder
13/03/13
CT1 Appendix 3B and Entitlement Offer Update
01/03/13
CT1 Cleansing Notice
01/03/13
CT1 Half Yearly Report and Accounts
28/02/13
CT1 Top 20 Shareholders and Option Spread
25/02/13
CT1 Change of Director's Interest Notice - N Weston
22/02/13
CT1 Change of Director's Interest Notice - A Lee
22/02/13
CT1 Change of Director's Interest Notice - C McNamara
22/02/13
CT1 Appendix 3B
21/02/13
CT1 Rights Issue Acceptances and Shortfall
21/02/13
CT1 Research Coverage Updated
18/02/13
CT1 Rights Issue Update
12/02/13
CT1 Investor Presentation
12/02/13
CT1 Cleansing Notice
04/02/13
CT1 Cleansing Notice
04/02/13
CT1 Appendix 3B
04/02/13
CT1 Agenix secures $3 Million Continuous Investment Agreement
31/01/13PRICE SENSITIVE
CT1 Appendix 4D Preliminary Half Year Report
22/01/13PRICE SENSITIVE
CT1 Appendix 4C - quarterly
22/01/13PRICE SENSITIVE
CT1 Entitlement Offer Timetable and Shareholder Letter
22/01/13
CT1 Appendix 3B
21/01/13
CT1 Non-Renounceable Entitlement Offer Prospectus
21/01/13PRICE SENSITIVE
CT1 Change of Director's Interest Notice
07/01/13
CT1 Cleansing Notice
07/01/13
CT1 Appendix 3B
07/01/13
CT1 Working Capital update and removal of trading halt
27/12/12PRICE SENSITIVE
CT1 Change in substantial holding
24/12/12
CT1 Request for Trading Halt
21/12/12
CT1 Trading Halt
21/12/12PRICE SENSITIVE
CT1 Results of Extraordinary General Meeting
20/12/12
CT1 Extraordinary General Meeting Presentation
20/12/12
CT1 Becoming a substantial holder
17/12/12
CT1 Change in substantial holding
13/12/12
CT1 Change of Director's Interest Notice
13/12/12
CT1 Change of Director's Interest Notice
13/12/12
CT1 Change of Director's Interest Notice
13/12/12
CT1 Agenix Update and Milestones for 2013
11/12/12
CT1 Cleansing Notice
04/12/12
CT1 Cleansing Notice
04/12/12
CT1 Appendix 3B
04/12/12
CT1 Notice of Extraordinary General Meeting/Proxy Form
22/11/12
CT1 Completion of Share Consolidation
16/11/12
CT1 Cleansing Notice - Tyrian
02/11/12
CT1 Cleansing Notice - Fortrend
02/11/12
CT1 Appendix 3B
02/11/12
CT1 Share Consolidation
29/10/12
CT1 Results of Annual General Meeting
25/10/12
CT1 +Tyrian Licenses Diagnostic Technology To Agenix
25/10/12
CT1 Annual General Meeting Presentation
25/10/12
CT1 Chairman's Address to Shareholders
25/10/12PRICE SENSITIVE
CT1 +Agenix acquires diagnostic device technology from Tyrian Ltd
25/10/12PRICE SENSITIVE
CT1 Microcap Investor Presentation
17/10/12
CT1 Appendix 4C - quarterly
11/10/12PRICE SENSITIVE
CT1 Notice of Annual General Meeting/Proxy Form
21/09/12
CT1 Annual Report to shareholders
06/09/12
CT1 Cleansing Notice
06/09/12
CT1 Appendix 3B
06/09/12
CT1 Agenix Presentation at International Forum
05/09/12
CT1 Agenix featured at International Forum
05/09/12PRICE SENSITIVE
CT1 Preliminary Final Report
24/08/12PRICE SENSITIVE
CT1 Change in Substantial Shareholder Notice
02/08/12
CT1 Cleansing Notice
02/08/12
CT1 Appendix 3B
02/08/12
CT1 Quarterly Update and Appendix 4C
30/07/12
CT1 Appendix 4C - quarterly
30/07/12PRICE SENSITIVE
CT1 Cleansing Notice
02/07/12
CT1 Appendix 3B
02/07/12
CT1 Lapse of Listed Options
02/07/12
CT1 Potential of Thromboview Diagnostic showcase to US Investors
15/06/12
CT1 Change in substantial holding
06/06/12
CT1 Agenix Hires Former Pfizer Worldwide Business Dev Director
04/06/12
CT1 Appendix 3B
04/06/12
CT1 Cleansing Notice
04/06/12
CT1 Option Expiry Notice
31/05/12
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
0.2¢ 		Change
0.000(0.00%) 		Mkt cap ! $1.474M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
31 23495490 0.1¢
 

Sellers (Offers)

Price($) Vol. No.
0.2¢ 222518 2
View Market Depth
Last trade - 16.12pm 25/11/2024 (20 minute delay) ?
CT1 (ASX) Chart

Top Stories

ASX Market Open: Bessent hype, Lebanon ceasefire hopes push Aus markets higher | November 26, 2024

A rollercoaster ride in on Wall Street @ capped by a Dow Jones record @ and reports of an impending Israel-Hezbollah ceasefire have both buoyed Australian futures, with the ASX 200 expected to rise 0.17% at open today.Forget @Trump trade;” the U.S. rally has been super-charg...
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.